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Potential Clinical Applications of
the HeartMate II Risk Score*
Wayne C. Levy, MD
Seattle, Washington
In this issue of the Journal, Cowger et al. (1) report
erivation and validation of the HeartMate II Risk Score
HMRS) within the HeartMate II clinical trials for bridge
o transplant (BTT) and destination therapy (DT) in 1,112
atients (1). They found that 5 variables in the derivation
ohort were predictive of 90-day survival after a HeartMate
I (HMII) left ventricular assist device (LVAD) (Thoratec,
leasanton, California): advanced age, low albumin, ele-
ated creatinine, elevated international normalized ratio
INR), and a LVAD implant volume of 15 total implants
uring the trials. The model was robust with a 7-fold
ifference in 90-day mortality between the low- and high-
isk groups (4% vs. 29%). A validated multivariate risk score
ould be extremely helpful in selection of patients at such
igh risk that they are unlikely to survive even with a
VAD, so-called futile implants. Evaluation of the mortal-
ty risk with medical therapy versus LVAD implantation is
mperative as LVADs are expanded into the ambulatory
on–inotrope-dependent patients who might have a poor
uality of life but might not be at high risk of mortality with
edical therapy (Interagency Registry for Mechanically
ssisted Circulatory Support [INTERMACs] 4 to 6). Does
he HMRS accomplish this goal?
See page 313
Five different LVAD risk models are compared in Table 1.
Right heart failure has long been recognized as a significant
risk factor for mortality in devices that provide primarily left
ventricular support and might acutely worsen right ventric-
ular support. The authors developed the Michigan Right
Ventricular Failure Risk Score. The model end-stage liver
disease score (MELD) was developed for patients undergo-
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Heart, Lung and Blood Institute Randomized Evaluation of VAD Intervention
Before Inotropic Therapy trial.ing transjugular intrahepatic portosystemic shunt using
indicators of multisystem organ dysfunction and coagulopa-
thy has been used for LVAD risk stratification (2). Other
investigators have suggested that an INR elevated by warfarin
oes not carry the same risk of death as an INR elevated in
he absence of warfarin, because many patients being eval-
ated for LVADs are currently receiving warfarin therapy
3). The destination therapy risk score (DTRS) was devel-
ped to predict HeartMate XVE (Thoratec) 90-day in-
ospital mortality.
Patient risk and selection is one aspect of perioperative
isk, but the skills of the surgeon in the operating room and
he multidisciplinary team in the hospital and ambulatory
etting are critical as well. Lietz et al. (4) evaluated the total
umber of DT HeartMate XVEs implanted as DT and
ound that the first 10 patients at an institution had an
levated risk for 30-day (17.5% vs. 8.3%) and 1-year
ortality. Most of the reduction in 30-day mortality with
T experience was found to be due to selection of lower-
isk patients with greater experience.
The HMRS validates previous risk markers seen in heart
ailure and LVAD risk models, including advanced age,
nflammation/malnutrition (low albumin), right heart fail-
re (elevated INR), cardiorenal syndrome (creatinine), and
enter experience (15 LVADs implanted). Many bio-
arkers have an inverse relationship with inflammation,
ncluding albumin, total protein, cholesterol, and hemoglo-
in; all of these were significant in the univariate analysis,
lthough only albumin was retained in the final model.
ilirubin was not found to be a univariate or multivariate
redictor, unlike prior reports with the MELD score or the
th INTERMACS report (5). Measures of pulmonary
ypertension, right ventricular function, intra-aortic balloon
ump, vasopressors, and inotropes were not predictors.
In the derivation cohort, the area under the receiver-
perating characteristic curve (AUC) was high (0.77) and
uperior to the MELD and DTRS. Importantly, with the
MII—unlike the HM XVE—the authors did not identify
futile group. The high-risk group had a 2-year survival of
0% with the HMII LVAD, similar to the 2-year survival in
he lowest-risk group with HM XVE LVAD (48%) (6).
he 90-day mortality of the high- versus low-HMRS group
as 7-fold higher (29% vs. 4%), and the 2-year mortality
emained 2-fold higher (22% vs. 50%) in the derivation
ohort.
In the validation cohort, the calibration of the model was
dequate, but the discrimination of the model was signifi-
antly lower, mainly due to a doubling of mortality in the
ow-risk group (8% vs. 4%). This resulted in only an
pproximate 3-fold difference in risk between the low- and
igh-risk groups (8% vs. 25%) versus a 7-fold difference in
he derivation cohort. The AUC for the HMRS in the
erivation versus validation cohorts fell from 0.77 to 0.64.
lthough the AUC was numerically higher for the HMRS
; BUN
I .
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MELD or DTRS (p  0.05) in the validation cohort.
Why was there such a decrease in the HMRS AUC
between the derivation and validation cohorts? It is uncer-
tain and may be due to chance. One reason may be the
method the authors choose to calculate LVAD experience.
In the paper by Lietz et al. (4), each patient was assigned to
the risk group on the basis of the LVAD number at that
center at the time of the implant (i.e., the first 10 patients at
each center are in the higher-risk group, even if the center
eventually implants 100 patients and only the 11th and
subsequent patient are in the lower-risk group). In the
HMRS model, the center volume was defined at the end of
the trials, rather than defining each patient as of the time of
HMII implantation. This method of estimating HMII
experience negates any associated risk with the first 14
HMIIs implants, provided a center eventually implanted
15 HMIIs and may overestimate the risk estimated as
doubled in the HMRS.
Although current warfarin use will increase the INR,
these patients had a trend to lower 90-day mortality (10%
vs. 14%) rather than the markedly elevated risk that would
be expected on the basis of the HMRS, which presumably
was higher in the warfarin patients due to the elevated INR,
which triples the risk for an INR of 2.2 versus 1.2. Although
warfarin use was not a univariate predictor, the authors did
not report whether it was a multivariate predictor, where it
would be anticipated to be associated with an improved
survival to offset the measured risk from the elevated INR.
For example, a 65-year-old individual with an albumin of
3.7, creatinine of 1.3, receiving an implant at a center with
15 LVADs implanted would be considered low risk if the
INR was 1.2 (HMRS  1.43, or approximately 6% 90-day
mortality) but high risk if the patient was taking warfarin
with an INR of 2.5 (HMRS of 2.91, or approximately 27%
90-day mortality). Warfarin use has significant implications
when trying to apply this model to ambulatory patients who
Comparison of LVAD Risk ScoresTable 1 Comparison of LVAD Risk Scores
RV Failure Risk Score (7) MEL
Bilirubin X X
INR X
Creatinine/BUN X X
Vasopressor use X
AST X
Age
Albumin
LVAD 15/center
Pulmonary artery pressure
Platelet count
Hematocrit
AUC derivation 0.73 (7) —
AUC validation 0.61–0.66 (8,9) 0.66
AST  aspartate aminotransferase; AUC  area under the receiver-operating characteristic curve
NR  international normalized ratio; LVAD  left ventricular assist device; RV  right ventricularare much more likely to be taking warfarin, because almostall patients taking warfarin would be categorized into the
moderate-to-higher risk group, where mortality improve-
ment at 1 year—on the basis of the HMRS—may be
minimal, because these non–inotrope-dependent ambula-
tory patients likely have a 25% to 50% 1-year mortality with
medical therapy versus 28% to 42% 1-year mortality with
the HMII as estimated by the HMRS.
The HMRS is the first prospectively validated multivar-
iate risk score for LVAD patients. In the current era of
patient selection, the model failed to identify patients who
were too high risk for implantation of a continuous flow
device (i.e., futile LVAD). It may provide effective discrim-
ination for INTERMACS 1 to 3 patients (approximately
6% to approximately 27% 90-day mortality). As currently
implemented, in ambulatory heart failure patients taking
warfarin, it does not allow you to identify low-risk patients
to consider for earlier LVAD implantation. As an example,
a 50-year-old patient with albumin of 4.5, creatinine of 1.0,
and INR of 2.5 due to warfarin, in a center with LVAD
volume 15, would be in the intermediate-risk group with
an estimated 1-year mortality of approximately 28%
(HMRS 1.70). Further HMRS validation is necessary, and
unless the AUC approaches 0.7 in other validation cohorts,
the HMRS may have limited clinical utility in the selection
of patients for HMIIs.
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